NDAINJECTIONINJECTABLE
Approved
Nov 1942
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
DEMEROL (meperidine hydrochloride) by Pfizer is morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 1942.
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMEROL (meperidine hydrochloride) is an injectable opioid analgesic approved in 1942 that acts as a mu-opioid receptor agonist to provide analgesia and sedation. It is indicated for severe pain requiring opioid therapy when alternative treatments are inadequate. The drug works through central nervous system effects on opioid receptors, with principal therapeutic value in pain management and sedation.
$0.071MPart D
LOE ApproachingDeclining
As LOE approaches, the commercial team faces portfolio consolidation pressures with declining spending and minimal Medicare utilization suggesting limited growth opportunities.
Mechanism of Action
morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value are analgesia and sedation.
Worked on DEMEROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.